1. Home
  2. SBFG vs IPHA Comparison

SBFG vs IPHA Comparison

Compare SBFG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SB Financial Group Inc.

SBFG

SB Financial Group Inc.

HOLD

Current Price

$21.67

Market Cap

139.7M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

N/A

Current Price

$1.41

Market Cap

141.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SBFG
IPHA
Founded
1983
1999
Country
United States
France
Employees
N/A
163
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.7M
141.7M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
SBFG
IPHA
Price
$21.67
$1.41
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
5.8K
23.6K
Earning Date
04-23-2026
03-26-2026
Dividend Yield
2.91%
N/A
EPS Growth
27.33
N/A
EPS
2.19
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
$9.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.10
$1.18
52 Week High
$23.93
$2.63

Technical Indicators

Market Signals
Indicator
SBFG
IPHA
Relative Strength Index (RSI) 52.66 46.46
Support Level $20.94 $1.18
Resistance Level $22.70 $1.80
Average True Range (ATR) 0.68 0.08
MACD -0.07 -0.00
Stochastic Oscillator 50.99 23.26

Price Performance

Historical Comparison
SBFG
IPHA

About SBFG SB Financial Group Inc.

SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in a single segment, which is Banking.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: